CAU
AMED

Caxton Associates (UK)’s Amedisys AMED Stock Holding History

Caxton Associates (UK)’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-154,321
Closed -$15.2M – 688
2025
Q2 		$15.2M Buy
154,321
+322
+0.2% +$30.5K 0.39% 34
2025
Q1 		$14.3M Buy
+153,999
New +$14.2M 0.5% 26

Other funds holding AMED

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MCI
MRP Capital Investments Alpharetta, Georgia $115M AUM 48.08% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Caxton Associates (UK)'s AMED Position: Q3 2025 in Review

Caxton Associates (UK) sold out of Amedisys (AMED) in Q3 2025, closing a stake of 154,321 shares — an estimated $15.2M sold.

Caxton Associates (UK) first reported a position in AMED in Q1 2025 and held it in 2 quarters. The position peaked at $15.2M in Q2 2025. 4 funds tracked by Wall St. Rank hold AMED as of Q3 2025.

  • Caxton Associates (UK) reported no remaining Amedisys position as of Q3 2025 after selling out during the quarter.
  • Caxton Associates (UK) sold 154,321 Amedisys shares in Q3 2025, an estimated $15.2M.
  • Caxton Associates (UK) first reported a position in Amedisys in Q1 2025 and held it in 2 quarters.
  • Caxton Associates (UK)'s Amedisys position peaked at $15.2M in Q2 2025.
  • 4 funds tracked by Wall St. Rank held Amedisys as of Q3 2025.

Based on Caxton Associates (UK)'s 13F filing for Q3 2025, filed 17 Nov 2025.